GlassScriptPhysician profile
Silus Motamarry
NPI 1861634354
$2,486.11
in general payments reported to CMS, 2019-2025
19 companies · $197 in 2025
The $197 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $445 · 2020: $23.56 · 2021: $356 · 2022: $229 · 2023: $258 · 2024: $978 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $884 · Travel and Lodging: $549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $883.92 |
| Travel and Lodging | $548.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $864.75 | 2022-2024 | Stellaris Elite, Envista Aspire Iol, Teneo |
| Alcon Vision LLC | $523.94 | 2019-2025 | Clareon, Clareon Panoptix Pro, Tryptyr |
| Abbvie INC. | $255.72 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $159.01 | 2019-2021 | |
| Horizon Therapeutics Plc | $137.03 | 2022-2023 | Tepezza |
| Carl Zeiss Meditec USA, INC. | $108.61 | 2021 | |
| Sun Pharmaceutical Industries INC. | $74.30 | 2019-2023 | Cequa |
| Allergan, INC. | $71.65 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $42.92 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $38.48 | 2022-2023 | Tyrvaya |
| Dompe US, INC. | $33.93 | 2024-2025 | Oxervate |
| Amgen INC. | $29.35 | 2024 | Tepezza |
| Glaukos Corporation | $25.81 | 2023 | |
| Johnson & Johnson Vision Care, INC. | $25.31 | 2019 | |
| Aerie Pharmaceuticals, INC. | $24.06 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $21.92 | 2024 | Iyuzeh |
| Harrow Eye, LLC | $19.74 | 2025 | Vevye |
| Rxsight INC | $15.82 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Ocular Therapeutix, INC. | $13.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Silus Motamarry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.